Artbio, a clinical-stage radiopharmaceutical company developing cancer therapies, announced a $132 million Series B round as it approaches clinical trials.
Why it matters: The biotech will "very likely" fundraise again in 2026, co-founder and CEO Emanuele Ostuni tells Axios Pro.
